The Health Care M&A Monthly: Mylan Wins Merck’s Generics Unit
Email Editor Several months of guessing ended this month when Mylan Laboratories (NYSE: MYL) announced a deal to buy Merck KGaA’s (DE: MRCG) generic pharmaceutical business for $6.7 billion (€4.9 billion) in cash. In so doing, Mylan beat out a number of competitors to...The Health Care M&A Monthly: May’s M&A Activity Strong 72 Deals Announced Worth $28.4 Billion
The month of May saw the announcement of 72 mergers and acquisitions in the 13 sectors of the health care industry. The four sectors of the health care technology segment accounted for 38 of those transactions, or 53% of the total, while the nine sectors of the health...The Health Care M&A Monthly: Hospice Care: End of the Continuum
Three Ways to Add Hospice Services to Your Senior Facility Email Editor Adding hospice care to the services offered in a senior facility is an additional benefit for residents — one that means they don’t have to move to receive end-of-life care. Moving is one of the...The Health Care M&A Monthly: Private Equity In The Middle Market-
Private Equity Firms Continue To Find Good Deals Email Editor Financial entities, such as REITS and private equity firms, continue to make their mark in the health care M&A market. During April, financial concerns were involved in 11 transactions, either as...The Health Care M&A Monthly: AstraZeneca Grabs MedImmune-$15.2 Billion Deal Is Largest Biotech Transaction Ever
Email Editor April’s M&A market produced the largest biotechnology deal ever seen. Britain’s AstraZeneca plc (NYSE: AZN) announced that it is buying MedImmune (NASDAQ: MEDI) for $58.00 per share, or $15.2 billion. In AZN’s sights are MEDI’s vaccine business and...Schedule a demo
Gain access to the best healthcare and long-term care investment intelligence, data, and analysis.
